NFG
AUPH icon

Noven Financial Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Noven Financial Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-14,650
Closed -$66K – 33
2017
Q4 		$66K Buy
14,650
+650
+5% +$3.61K 0.04% 32
2017
Q3 		$88K Buy
+14,000
New +$88.3K 0.05% 31

Other funds holding AUPH

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Noven Financial Group's AUPH Position: Q1 2018 in Review

Noven Financial Group sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2018, closing a stake of 14,650 shares — an estimated $66K sold.

Noven Financial Group first reported a position in AUPH in Q3 2017 and held it in 2 quarters. The position peaked at $88K in Q3 2017. 64 funds tracked by Wall St. Rank hold AUPH as of Q1 2018.

  • Noven Financial Group reported no remaining Aurinia Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Noven Financial Group sold 14,650 Aurinia Pharmaceuticals shares in Q1 2018, an estimated $66K.
  • Noven Financial Group first reported a position in Aurinia Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Noven Financial Group's Aurinia Pharmaceuticals position peaked at $88K in Q3 2017.
  • 64 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2018.

Based on Noven Financial Group's 13F filing for Q1 2018, filed 9 May 2018.